ICH Approves GCP Guideline Amendment
Applied Clinical Trials
The Council adopts revision encouraging sponsors to implement improved oversight and management of clinical trials.
The International Council for Harmonization (ICH) has adopted an important revision to the global good clinical practice (GCP) guideline. The amendment, ICH E6(R2), aims to encourage sponsors to implement improved oversight and management of clinical trials, while continuing to ensure protection of human subjects participating in trials and clinical trial data integrity.
This amendment will be implemented by ICH members through national and regional guidance. Also, the ICH Assembly has agreed to look at renewing the wider package of guidelines that relate to GCP and clinical trial design. This will include updating current guidance on interventional trials and expanding on novel trial methodologies for drug registration such as non-interventional trials, including use of new data sources like real-world evidence, patient registries, etc., according to an ICH statement issued last month.
A reflection paper is expected to be published on the ICH website in early 2017. It will include an outline of the long-term strategy, starting with revision of the ICH E8 guideline in 2017.
Optimizing safety data collection
Recognizing the increased interest in collecting data on the long-term effects of drugs, the Assembly also decided to begin work on development of a new guideline on optimization of safety data collection.
The Assembly expects the new guideline (future ICH E19) to harmonize requirements on the optimal collection of safety data during late-stage, pre-market and post-approval clinical investigations of new drugs and new indications for approved drugs. This will improve global health by encouraging study on long-term effects, rare events and new indications of drugs through reducing resources required for these studies, noted the ICH.
Individual case safety reports (ICSRs) have an important role in supporting drug safety surveillance by regulators around the world, the ICH said. The Assembly agreed to an update on the implementation guide for the ICH ICSR guideline (ICH E2B(R3)), as well as the question and answer document.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
